Page 1

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington , D.C. 20549 FORM 10 - Q ( Mark One ) ☑ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15 ( d ) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30 , 2021 TRANSITION REPORT PURSUANT TO SECTION 13 OR 15 ( d ) OF THE SECURITIES EXCHANGE ACT OF ☐ 1934 For the transition period from Delaware to Commission File No. 001-37704 DarioHealth Corp. ( Exact name of registrant as specified in its charter ) ( State or other jurisdiction of incorporation or organization ) 142 W. 57th St. , 8th Floor New York , New York ( Address of Principal Executive Offices ) ( 646 ) 665-4667 45-2973162 ( I.R.S. Employer Identification No. ) ( Registrant's telephone number , including area code ) n / a 10019 ( Zip Code ) ( Former name , former address and former fiscal year , if changed since last report ) Securities registered pursuant to Section 12 ( b ) of the Act : Title of each class Common Stock , par value $ 0.0001 per share Trading Symbol ( s ) DRIO Name of exchange on which registered The Nasdaq Capital Market LLC Indicate by check mark whether the registrant ( 1 ) has filed all reports required to be filed by Section 13 or 15 ( d ) of the Securities Exchange Act of 1934 during the preceding 12 months ( or for such shorter period that the registrant was required to file such reports ) , and ( 2 ) has been subject to such filing requirements for the past 90 days . Yes > No □ Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S - T ( § 232.405 of this chapter ) during the preceding 12 months ( or for such shorter period that the registrant was required to submit such files ) . Yes > No ☐ Indicate by check mark whether the registrant is a large accelerated filer , an accelerated filer , a non - accelerated filer , a smaller reporting company , or an emerging growth company . See the definitions of “ large accelerated filer , ” “ accelerated filer , " " smaller reporting company , ” and “ emerging growth company ” in Rule 12b - 2 of the Exchange Act . ☐ Large accelerated filer ☑ Non - accelerated filer ☐ Accelerated filer ☑ ☐ Smaller reporting company Emerging growth company If an emerging growth company , indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13 ( a ) of the Exchange Act . □ Indicate by check mark whether the registrant is a shell company ( as defined in Rule 12b - 2 of the Exchange Act ) . Yes No ☑ As of November 12 , 2021 , the registrant had 16,575,633 shares of common stock outstanding . When used in this quarterly report , the terms “ DarioHealth , ” “ the Company , ” “ we , ” “ our , ” and “ us ” refer to DarioHealth Corp. , a Delaware corporation , our subsidiaries LabStyle Innovation Ltd. and Upright Technologies Ltd. , each of which are Israeli companies , and Upright Technologies Inc. and PsyInnovations Inc. , each a Delaware company . “ Dario ” is registered as a trademark in the United States , Israel , China , Canada , Hong Kong , South Africa , Japan , Costa Rica and Panama . " DarioHealth " is registered as a trademark in the United States and Israel .